Summary of Study ST003167

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001970. The data can be accessed directly via it's Project DOI: 10.21228/M8314P This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003167
Study TitleMetabolomics of Human CD19-BBz CD8 CAR-T cells with low and high MCJ expression
Study SummaryThe goal of these experiments are to characterize the metabolic profile of the human CD8 CD19-BBz CAR-T cells from donors with high or low MCJ expression after 3 expansions (6 days) with IL-2 (100IU/ml).
Institute
University of Colorado School of Medicine
LaboratoryLaboratory of Angelo D'Alessandro in collaboration with Mercedes Rincon
Last NameCendali
First NameFrancesca
Address13199 East Montview Boulevard, Aurora, CO, 80045, USA
Emailfrancesca.cendali@cuanschutz.edu
Phone3037246131
Submit Date2024-04-11
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2024-05-02
Release Version1
Francesca Cendali Francesca Cendali
https://dx.doi.org/10.21228/M8314P
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR001970
Project DOI:doi: 10.21228/M8314P
Project Title:Releasing the mitochondrial respiration brake MCJ/DnaJC15 enhances CD8 CAR-T cell therapy efficacy
Project Summary:Metabolism of chimeric antigen receptor (CAR) T cells is emerging as an important area to improve CAR-T cell therapy in cancer treatment. Mitochondrial respiration is essential for survival and function of CAR-T cells, but developing strategies to specifically enhance mitochondrial respiration has been challenging. Here we identify MCJ/DnaJC15, an endogenous negative regulator of mitochondrial Complex I, as a metabolic target to enhance mitochondrial respiration in CD8 CAR-T cells. Loss of MCJ in CD8 CAR-T cells increases their in vitro and in vivo efficacy against mouse B cell leukemias. MCJ deficiency in TCR- specific CD8 cells also increases their efficacy against solid tumors in vivo. Furthermore, we reveal that human CD8 cells express MCJ and that silencing MCJ expression increases mitochondrial metabolism and anti-tumor activity of human CAR-T cells. Thus, targeting MCJ to enhance mitochondrial metabolism is a promising therapeutic strategy to improve the efficacy of adoptive T cell therapies.
Institute:University of Colorado School of Medicine
Laboratory:Laboratory of Angelo D'Alessandro in collaboration with Mercedes Rincon
Last Name:Cendali
First Name:Francesca
Address:13199 East Montview Boulevard, Aurora, CO, 80045, USA
Email:francesca.cendali@cuanschutz.edu
Phone:3037246131

Subject:

Subject ID:SU003286
Subject Type:Cultured cells
Subject Species:Homo sapiens

Factors:

Subject type: Cultured cells; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Factor Sample source
SA343035D26 19BBz_4high 19BBz T-Cells
SA343036D26 19BBz_3high 19BBz T-Cells
SA343037D26 19BBz_2high 19BBz T-Cells
SA343038D16 19BBz_3low 19BBz T-Cells
SA343039D16 19BBz_4low 19BBz T-Cells
SA343040D16 19BBz_2low 19BBz T-Cells
Showing results 1 to 6 of 6

Collection:

Collection ID:CO003279
Collection Summary:Human CD8 cells were isolated with positive selection as described. The CD8 cells were activated with anti-CD3/anti-CD28 beads (Dynabeads™ Human T-Expander CD3/CD28, Gibco), as previously described107. After 48h activation, the CD8 cells were spun (1000xg for 2h at 32C) with lentiviral supernatant containing CD19-BBz/shMCJ-1 CAR, CD19-BBz/shMCJ-2 CAR or CD19-BBz/shMCJ-2 CAR construct-packing virus with rhIL-2 (40 IU/ml) and protamine sulfate. After transduction, the anti-CD3/anti-CD28 beads were removed and CD8 cells were expanded with rhIL-2 (100 IU/ml) for the specified number of days.
Sample Type:T-cells

Treatment:

Treatment ID:TR003295
Treatment Summary:The human CD19-BBz shRNA CAR lentiviral constructs were based on a previously described CD19-BBz CAR containing the human CD19-binding scFV FMC63, CD8 hinge domain, 4-1BB costimulatory domain and CD3 chain105. Using CD19-BBz CAR plasmid as a cloning vector, we generated multiple vectors where we incorporated the RNA polymerase III U6 promotor (on the 3' of the CD3 chain domain) followed by an shRNA: 1) a CD19-BBz/shMCJ-1 CAR construct containing the shMCJ-1 5’-GAAGATTTCAACTCCTAGC-3’ sequence106, 2) a CD19-BBz/shMCJ-2 CAR construct containing the shMCJ-2; 5’-AACCTCTAGAACAAGTTATC-3’, and 3) a CD19-BBz/c-shRNA CAR vectors expressing the shRNA encoding scramble sequences. Lentiviral supernatant was produced in the LentiX-293T packaging cell line (Clonetech) as previously described. Lentiviral supernatants were collected after 48 hours post-transfection.

Sample Preparation:

Sampleprep ID:SP003293
Sampleprep Summary:CAR-T cells were isolated as described above either from in vitro culture or from bone marrow harvested in an in vivo study. The cells were washed in PBS and frozen at -80C until the assay is ready to run. Metabolites from cells were extracted at 2x106 cells/ml at 4°C (30 min) in the presence of 5:3:2 MeOH:MeCN:water (v/v/v). The samples were spun down and the resulting supernatant was transferred to new tubes and dried under a vacuum. The resulting residue was reconstituted in 0.1% formic acid at a 3x concentration, then analyzed on a Thermo Vanquish UHPLC coupled to a Thermo Q Exactive MS as previously described in detail.

Combined analysis:

Analysis ID AN005196 AN005197
Analysis type MS MS
Chromatography type Reversed phase Reversed phase
Chromatography system Thermo Vanquish Thermo Vanquish
Column Phenomenex Kinetex C18 (30 x 2.1mm, 1.7um) Phenomenex Kinetex C18 (30 x 2.1mm, 1.7um)
MS Type ESI ESI
MS instrument type Exploris120 Exploris120
MS instrument name Thermo Q Exactive Orbitrap Thermo Q Exactive Orbitrap
Ion Mode NEGATIVE POSITIVE
Units Peak Areas Peak Areas

Chromatography:

Chromatography ID:CH003931
Chromatography Summary:Negative ion Mode
Instrument Name:Thermo Vanquish
Column Name:Phenomenex Kinetex C18 (30 x 2.1mm, 1.7um)
Column Temperature:45
Flow Gradient:0-0.2 min 5% B, 0.2-.8 min hold at 95% B, .8-.81 min 95-5% B, .81-1 min hold at 5% B.
Flow Rate:0.450 ml/min
Solvent A:100% Water; 10mM Ammonium acetate, .01% Formic Acid
Solvent B:50% Methanol/ 50% Acetonitrile; 10mM Ammonium acetate, .01% Formic Acid
Chromatography Type:Reversed phase
  
Chromatography ID:CH003932
Chromatography Summary:Positive Ion Mode
Instrument Name:Thermo Vanquish
Column Name:Phenomenex Kinetex C18 (30 x 2.1mm, 1.7um)
Column Temperature:45
Flow Gradient:0-0.3 min 5% B, 0.3-.8 min hold at 95% B, .8-.81 min 95-5% B, .81-1 min hold at 5% B.
Flow Rate:0.450 ml/min
Solvent A:100% water; 0.1% formic acid
Solvent B:100% acetonitrile; 0.1% formic acid
Chromatography Type:Reversed phase

MS:

MS ID:MS004929
Analysis ID:AN005196
Instrument Name:Thermo Q Exactive Orbitrap
Instrument Type:Exploris120
MS Type:ESI
MS Comments:Resolution 70,000, scan range 65-900 m/z, maximum injection time 200 ms, microscans 2, automatic gain control (AGC) 3 x 10^6 ions, source voltage 4.0 kV, capillary temperature 320 C, and sheath gas 45, auxiliary gas 15, and sweep gas 0 (all nitrogen). Data converted to mzXML using RawConverter. Metabolites were annotated and integrated using Maven in conjunction with the KEGG database.
Ion Mode:NEGATIVE
  
MS ID:MS004930
Analysis ID:AN005197
Instrument Name:Thermo Q Exactive Orbitrap
Instrument Type:Exploris120
MS Type:ESI
MS Comments:Resolution 70,000, scan range 65-900 m/z, maximum injection time 200 ms, microscans 2, automatic gain control (AGC) 3 x 10^6 ions, source voltage 4.0 kV, capillary temperature 320 C, and sheath gas 45, auxiliary gas 15, and sweep gas 0 (all nitrogen). Data converted to mzXML using RawConverter. Metabolites were annotated and integrated using Maven in conjunction with the KEGG database.
Ion Mode:POSITIVE
  logo